These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2021 related items for PubMed ID: 17100405

  • 1. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R, Anolik JH.
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [Abstract] [Full Text] [Related]

  • 2. B-cell biology and related therapies in systemic lupus erythematosus.
    Ahmed S, Anolik JH.
    Rheum Dis Clin North Am; 2010 Feb; 36(1):109-30, viii-ix. PubMed ID: 20202594
    [Abstract] [Full Text] [Related]

  • 3. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR, Gordon C.
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [Abstract] [Full Text] [Related]

  • 4. New treatments for SLE: cell-depleting and anti-cytokine therapies.
    Anolik JH, Aringer M.
    Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):859-78. PubMed ID: 16150407
    [Abstract] [Full Text] [Related]

  • 5. B-cell-targeted therapy for systemic lupus erythematosus: an update.
    Ding C, Foote S, Jones G.
    BioDrugs; 2008 Oct; 22(4):239-49. PubMed ID: 18611066
    [Abstract] [Full Text] [Related]

  • 6. B cell biology and dysfunction in SLE.
    Anolik JH.
    Bull NYU Hosp Jt Dis; 2007 Oct; 65(3):182-6. PubMed ID: 17922667
    [Abstract] [Full Text] [Related]

  • 7. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R, Albert D.
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [Abstract] [Full Text] [Related]

  • 8. B cell biology: implications for treatment of systemic lupus erythematosus.
    Anolik JH.
    Lupus; 2013 Apr; 22(4):342-9. PubMed ID: 23553777
    [Abstract] [Full Text] [Related]

  • 9. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells.
    Looney RJ, Anolik J, Sanz I.
    Lupus; 2004 Apr; 13(5):381-90. PubMed ID: 15230297
    [Abstract] [Full Text] [Related]

  • 10. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

  • 11. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians.
    Sanchez-Niño MD, Ortiz A.
    Nephrol Dial Transplant; 2015 Mar 20; 30(3):394-400. PubMed ID: 24914092
    [Abstract] [Full Text] [Related]

  • 12. BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.
    Vincent FB, Morand EF, Mackay F.
    Immunol Cell Biol; 2012 Mar 20; 90(3):293-303. PubMed ID: 22231653
    [Abstract] [Full Text] [Related]

  • 13. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
    Drugs R D; 2008 Mar 20; 9(3):197-202. PubMed ID: 18457473
    [Abstract] [Full Text] [Related]

  • 14. The efficacy of novel B cell biologics as the future of SLE treatment: a review.
    Kamal A, Khamashta M.
    Autoimmun Rev; 2014 Nov 20; 13(11):1094-101. PubMed ID: 25149393
    [Abstract] [Full Text] [Related]

  • 15. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
    Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO.
    J Autoimmun; 2018 Jul 20; 91():45-54. PubMed ID: 29636274
    [Abstract] [Full Text] [Related]

  • 16. B cells targeting therapy in the management of systemic lupus erythematosus.
    Lee WS, Amengual O.
    Immunol Med; 2020 Mar 20; 43(1):16-35. PubMed ID: 32107989
    [Abstract] [Full Text] [Related]

  • 17. [Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].
    Tanaka Y.
    J UOEH; 2011 Jun 01; 33(2):173-81. PubMed ID: 21702122
    [Abstract] [Full Text] [Related]

  • 18. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, Isenberg DA, Gordon C, Ehrenstein MR.
    BMJ Open; 2019 Dec 16; 9(12):e032569. PubMed ID: 31848169
    [Abstract] [Full Text] [Related]

  • 19. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, Suzuki J, Nozawa K, Amano H, Tokano Y, Kobata T, Takasaki Y.
    Rheumatology (Oxford); 2007 Jul 16; 46(7):1083-6. PubMed ID: 17500077
    [Abstract] [Full Text] [Related]

  • 20. Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.
    Nakayamada S, Iwata S, Tanaka Y.
    Int J Rheum Dis; 2015 Feb 16; 18(2):208-18. PubMed ID: 25557245
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 102.